WEKO3
アイテム
{"_buckets": {"deposit": "4e95fb4f-100b-4e76-bc28-861465bcb1fa"}, "_deposit": {"created_by": 1, "id": "46651", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "46651"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00046651", "sets": ["1"]}, "author_link": ["465069", "465068", "465064", "465061", "465072", "465062", "465067", "465066", "465071", "465073", "465065", "465070", "465060", "465063", "465074"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2012-11", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "5", "bibliographicPageEnd": "30", "bibliographicPageStart": "624", "bibliographicVolumeNumber": "96", "bibliographic_titles": [{"bibliographic_title": "International Journal of Hematology"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "High-dose chemotherapy followed by autologous stem cell transplantation (auto-SCT) is widely used as a salvage therapy in the treatment of refractory malignant lymphoma. To investigate the safety and feasibility of a high-dose MCNU, carboplatin, etoposide and cyclophosphamide (MCVC) regimen, we conducted a prospective multicenter trial. Thirty patients with relapsed/refractory/poor-risk non-Hodgkin lymphoma (NHL n = 27) or Hodgkin lymphoma (HD n = 3) were uniformly treated with an MCVC regimen and underwent auto-SCT. The median follow-up duration of the surviving patients was 67 months (56-133 months). The major toxicities were anorexia (94 %), diarrhea (80 %), nausea (79 %), febrile neutropenia (70 %), alopecia (67 %) and mucositis (60 %). Three patients developed severe left ventricular dysfunction, and two patients developed severe sinusoidal obstructive syndrome (SOS). Of these patients, two died without disease progression. Treatment-related mortality was 6.6 %. Late-onset adverse events including two cases of cytomegalovirus pneumonia and one of interstitial pneumonia were observed. In DLBCL (n = 13) and transformed FL (n = 2) patients, OS and EFS at 3 years were 72 and 46 %, respectively. These results suggest that the MCVC regimen followed by auto-SCT is a feasible and tolerable therapy for relapsed/refractory malignant lymphoma. However, cardiac toxicity due to high-dose cyclophosphamide and development of SOS can occur and should be carefully monitored. Further follow-up is needed to evaluate the long-term efficacy and safety of this regimen.", "subitem_description_type": "Abstract"}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "0925-5710", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kameoka, Yoshihio"}], "nameIdentifiers": [{"nameIdentifier": "465060", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takahashi, Naoto"}], "nameIdentifiers": [{"nameIdentifier": "465061", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishizawa, Keniti"}], "nameIdentifiers": [{"nameIdentifier": "465062", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kato, Yuichi"}], "nameIdentifiers": [{"nameIdentifier": "465063", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ito, Jugo"}], "nameIdentifiers": [{"nameIdentifier": "465064", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sasaki, Osamu"}], "nameIdentifiers": [{"nameIdentifier": "465065", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Murai, Katzunori"}], "nameIdentifiers": [{"nameIdentifier": "465066", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Noji, Hideyoshi"}], "nameIdentifiers": [{"nameIdentifier": "465067", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hirokawa, Makoto"}], "nameIdentifiers": [{"nameIdentifier": "465068", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tajima, Katsushi"}], "nameIdentifiers": [{"nameIdentifier": "465069", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shichishima, Tsutomu"}], "nameIdentifiers": [{"nameIdentifier": "465070", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishida, Yoji"}], "nameIdentifiers": [{"nameIdentifier": "465071", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Harigae, Hideo"}], "nameIdentifiers": [{"nameIdentifier": "465072", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sawada, Kenichi"}], "nameIdentifiers": [{"nameIdentifier": "465073", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "田嶋 克史", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "465074", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Safety and feasibility of high-dose ranimustine(MCNU), carboplatin, etoposide, and cyclophosphamide(MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Safety and feasibility of high-dose ranimustine(MCNU), carboplatin, etoposide, and cyclophosphamide(MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma."}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/46651", "pubdate": {"attribute_name": "公開日", "attribute_value": "2013-12-02"}, "publish_date": "2013-12-02", "publish_status": "0", "recid": "46651", "relation": {}, "relation_version_is_last": true, "title": ["Safety and feasibility of high-dose ranimustine(MCNU), carboplatin, etoposide, and cyclophosphamide(MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma."], "weko_shared_id": -1}
Safety and feasibility of high-dose ranimustine(MCNU), carboplatin, etoposide, and cyclophosphamide(MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma.
https://repo.qst.go.jp/records/46651
https://repo.qst.go.jp/records/466511bb58961-0f8c-4a6f-85ef-9b09a5c21429
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2013-12-02 | |||||
タイトル | ||||||
タイトル | Safety and feasibility of high-dose ranimustine(MCNU), carboplatin, etoposide, and cyclophosphamide(MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma. | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Kameoka, Yoshihio
× Kameoka, Yoshihio× Takahashi, Naoto× Ishizawa, Keniti× Kato, Yuichi× Ito, Jugo× Sasaki, Osamu× Murai, Katzunori× Noji, Hideyoshi× Hirokawa, Makoto× Tajima, Katsushi× Shichishima, Tsutomu× Ishida, Yoji× Harigae, Hideo× Sawada, Kenichi× 田嶋 克史 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | High-dose chemotherapy followed by autologous stem cell transplantation (auto-SCT) is widely used as a salvage therapy in the treatment of refractory malignant lymphoma. To investigate the safety and feasibility of a high-dose MCNU, carboplatin, etoposide and cyclophosphamide (MCVC) regimen, we conducted a prospective multicenter trial. Thirty patients with relapsed/refractory/poor-risk non-Hodgkin lymphoma (NHL n = 27) or Hodgkin lymphoma (HD n = 3) were uniformly treated with an MCVC regimen and underwent auto-SCT. The median follow-up duration of the surviving patients was 67 months (56-133 months). The major toxicities were anorexia (94 %), diarrhea (80 %), nausea (79 %), febrile neutropenia (70 %), alopecia (67 %) and mucositis (60 %). Three patients developed severe left ventricular dysfunction, and two patients developed severe sinusoidal obstructive syndrome (SOS). Of these patients, two died without disease progression. Treatment-related mortality was 6.6 %. Late-onset adverse events including two cases of cytomegalovirus pneumonia and one of interstitial pneumonia were observed. In DLBCL (n = 13) and transformed FL (n = 2) patients, OS and EFS at 3 years were 72 and 46 %, respectively. These results suggest that the MCVC regimen followed by auto-SCT is a feasible and tolerable therapy for relapsed/refractory malignant lymphoma. However, cardiac toxicity due to high-dose cyclophosphamide and development of SOS can occur and should be carefully monitored. Further follow-up is needed to evaluate the long-term efficacy and safety of this regimen. | |||||
書誌情報 |
International Journal of Hematology 巻 96, 号 5, p. 624-30, 発行日 2012-11 |
|||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 0925-5710 |